$IDYA
IDEAYA Biosciences, Inc. Stock $idya

$idya Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000156459022010922 Filed on March 18, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$11.36M	$2.962M	$27.94M
YoY Change	56.74%	-71.98%	43.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.923M	$5.221M	$20.05M
YoY Change	22.88%	37.39%	32.09%
% of Gross Profit
Research & Development	$19.66M	$16.11M	$58.16M
YoY Change	69.95%	33.69%	46.5%
% of Gross Profit
Depreciation & Amortization	$464.0K	$448.0K	$1.725M
YoY Change	21.47%	24.44%	24.91%
% of Gross Profit
Operating Expenses	$25.58M	$21.33M	$58.16M
YoY Change	56.14%	34.58%	5.97%
Operating Profit	-$14.22M		-$50.27M
YoY Change	55.67%		42.22%
Interest Expense	$207.0K	$157.0K	$506.0K
YoY Change	88.18%	4.67%	-40.47%
% of Operating Profit
Other Income/Expense, Net	$207.0K		$506.0K
YoY Change	81.58%		-40.4%
Pretax Income	-$14.01M	-$18.21M	-$49.76M
YoY Change	55.35%	254.32%	44.24%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$14.01M	-$18.21M	-$49.76M
YoY Change	55.34%	254.32%	44.26%
Net Earnings / Revenue	-123.36%	-614.85%	-178.1%
Basic Earnings Per Share	-$0.36		-$1.41
Diluted Earnings Per Share	-$363.1K	-$472.6K	-$1.412M
COMMON SHARES
Basic Shares Outstanding	38.63M		35.25M
Diluted Shares Outstanding	38.59M		35.25M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$252.6M	$246.8M	$246.8M
YoY Change	-16.44%	-12.99%	-12.99%
Cash & Equivalents	$55.29M	$92.05M	$92.05M
Short-Term Investments	$197.3M	$154.7M	$154.7M
Other Short-Term Assets	$2.753M	$3.123M	$3.123M
YoY Change	-5.07%	0.74%	0.74%
Inventory
Prepaid Expenses
Receivables	$697.0K	$1.103M	$1.103M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$256.0M	$251.0M	$251.0M
YoY Change	-16.92%	-13.03%	-13.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.274M	$4.763M	$8.661M
YoY Change	-45.06%	11.52%	-8.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$93.63M	$121.3M	$121.3M
YoY Change	1055.9%
Other Assets	$256.0K	$291.0K	$397.0K
YoY Change	28.0%	254.88%	98.5%
Total Long-Term Assets	$102.8M	$130.4M	$130.4M
YoY Change	474.4%	1248.83%	1243.82%
TOTAL ASSETS
Total Short-Term Assets	$256.0M	$251.0M	$251.0M
Total Long-Term Assets	$102.8M	$130.4M	$130.4M
Total Assets	$358.9M	$381.3M	$381.3M
YoY Change	10.05%	27.85%	27.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.364M	$2.100M	$2.100M
YoY Change	158.77%	120.36%	110.0%
Accrued Expenses	$12.63M	$12.32M	$14.02M
YoY Change	35.78%	44.67%	38.8%
Deferred Revenue	$39.22M	$29.04M
YoY Change		5.17%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$56.96M	$45.16M	$45.16M
YoY Change	57.78%	16.87%	16.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.24M	$34.67M	$34.67M
YoY Change	-76.68%	288850.0%	-43.53%
Total Long-Term Liabilities	$13.24M	$34.67M	$34.67M
YoY Change	-76.68%	288850.0%	-43.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$56.96M	$45.16M	$45.16M
Total Long-Term Liabilities	$13.24M	$34.67M	$34.67M
Total Liabilities	$70.20M	$79.83M	$79.83M
YoY Change	-24.52%	-20.16%	-20.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$190.8M	-$176.7M
YoY Change		39.19%
Common Stock	$482.2M	$479.0M
YoY Change		47.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$288.7M	$301.5M	$301.5M
YoY Change
Total Liabilities & Shareholders Equity	$358.9M	$381.3M	$381.3M
YoY Change	10.05%	27.85%	27.84%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$14.01M	-$18.21M	-$49.76M
YoY Change	55.34%	254.32%	44.26%
Depreciation, Depletion And Amortization	$464.0K	$448.0K	$1.725M
YoY Change	21.47%	24.44%	24.91%
Cash From Operating Activities	-$19.65M	-$16.66M	-$55.78M
YoY Change	43.16%	43.59%	-200.57%
INVESTING ACTIVITIES
Capital Expenditures	$401.0K	-$605.0K	$2.644M
YoY Change	-60.02%	236.11%	436.31%
Acquisitions
YoY Change
Other Investing Activities	-$17.36M	$192.0K	-$67.02M
YoY Change	-146.37%	-104.39%	-54.02%
Cash From Investing Activities	-$17.76M	-$413.0K	-$69.67M
YoY Change	-148.75%	-90.92%	-52.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$85.99M
YoY Change			-14.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	653.0K	688.0K	145.5M
YoY Change	-98.45%	-90.1%	12.97%
NET CHANGE
Cash From Operating Activities	-19.65M	-16.66M	-55.78M
Cash From Investing Activities	-17.76M	-413.0K	-69.67M
Cash From Financing Activities	653.0K	688.0K	145.5M
Net Change In Cash	-36.76M	-16.38M	20.01M
YoY Change	-156.8%	78.07%	-47.3%
FREE CASH FLOW
Cash From Operating Activities	-$19.65M	-$16.66M	-$55.78M
Capital Expenditures	$401.0K	-$605.0K	$2.644M
Free Cash Flow	-$20.05M	-$16.05M	-$58.42M
YoY Change	36.13%	40.56%	-206.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	us-gaap	Defined Contribution Plan Sponsor Location Extensible List DefinedContributionPlanSponsorLocationExtensibleList	http://fasb.org/us-gaap/2021-01-31#DomesticPlanMember
CY2020	us-gaap	Defined Contribution Plan Sponsor Location Extensible List DefinedContributionPlanSponsorLocationExtensibleList	http://fasb.org/us-gaap/2021-01-31#DomesticPlanMember
CY2019	us-gaap	Defined Contribution Plan Sponsor Location Extensible List DefinedContributionPlanSponsorLocationExtensibleList	http://fasb.org/us-gaap/2021-01-31#DomesticPlanMember
CY2021	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2020	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2019	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.900
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.849
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.772
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.036
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.983
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.855
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.006
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.003
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.014
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.015
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.025
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38915
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4268251
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 Shoreline Court
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2021	dei	City Area Code CityAreaCode	650
CY2021	dei	Local Phone Number LocalPhoneNumber	443-6209
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	629100000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38627222
CY2021	dei	Auditor Firm AuditorFirmId	238
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92046000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72037000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	154724000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	211548000
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1103000
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1877000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3123000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3143000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	250996000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	288605000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	106000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	106000
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	121293000
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4763000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4271000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3898000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5205000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	291000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	82000
CY2021Q4	us-gaap	Assets Assets	381347000
CY2020Q4	us-gaap	Assets Assets	298269000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2100000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	953000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12320000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8516000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	29040000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	27613000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1699000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1540000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	18000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45159000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38640000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	31192000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	56160000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3482000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5183000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12000
CY2021Q4	us-gaap	Liabilities Liabilities	79833000
CY2020Q4	us-gaap	Liabilities Liabilities	99995000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38533045
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38533045
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29537216
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29537216
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	478970000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	325250000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-712000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176748000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-126986000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58158000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39698000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15184000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9952000
CY2019	us-gaap	Operating Expenses OperatingExpenses	44271000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	301514000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	198274000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	381347000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	298269000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27941000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19538000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27941000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19538000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-719000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-58000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	96000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-48948000
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	138391000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	307000
CY2019	idya	Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares	114000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2168000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	96000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-41975000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	100400000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1202000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	326000
CY2020	idya	Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares	56000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3609000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-58000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-34495000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	198274000
CY2019	idya	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-1093000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	225000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4212000
CY2021	us-gaap	Profit Loss ProfitLoss	-49762000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1510000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	697000
CY2020	us-gaap	Profit Loss ProfitLoss	-34495000
CY2019	us-gaap	Profit Loss ProfitLoss	-41975000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1725000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1381000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1245000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1834000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-578000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	473000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8237000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3609000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2168000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-14000
CY2021	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0
CY2020	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	18000
CY2019	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	8000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-774000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1877000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	189000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	510000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1963000
CY2021	idya	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-1307000
CY2020	idya	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	148000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1166000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-23541000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	83773000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0
CY2021	idya	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1542000
CY2020	idya	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-49000
CY2019	idya	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1249000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55779000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	55463000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39313000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2644000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	493000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1353000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	314996000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	242314000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	88004000
CY2021	idya	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	243956000
CY2020	idya	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	96564000
CY2019	idya	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	73528000
CY2021	idya	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	4018000
CY2020	idya	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0
CY2019	idya	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	18094000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-69666000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-146243000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72143000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2265000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85990000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100664000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50321000
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	19988000
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2021	idya	Proceeds From Issuance Of Common Stock Related To At Market Offering Program Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts	57263000
CY2020	idya	Proceeds From Issuance Of Common Stock Related To At Market Offering Program Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts	6582000
CY2019	idya	Proceeds From Issuance Of Common Stock Related To At Market Offering Program Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts	0
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1504000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1190000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34067000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	106000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	106000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92152000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	289000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	697000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	326000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	145454000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	128750000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50610000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20009000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37970000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13562000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72143000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34173000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	71000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	82000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	91000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1191000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2021	idya	Vesting Of Early Exercised Options And Restricted Stock VestingOfEarlyExercisedOptionsAndRestrictedStock	24000
CY2020	idya	Vesting Of Early Exercised Options And Restricted Stock VestingOfEarlyExercisedOptionsAndRestrictedStock	56000
CY2019	idya	Vesting Of Early Exercised Options And Restricted Stock VestingOfEarlyExercisedOptionsAndRestrictedStock	114000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	92000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	520000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2021	idya	Conversion Of Redeemable Convertible Preferred Stock In To Common Stock ConversionOfRedeemableConvertiblePreferredStockInToCommonStock	0
CY2020	idya	Conversion Of Redeemable Convertible Preferred Stock In To Common Stock ConversionOfRedeemableConvertiblePreferredStockInToCommonStock	0
CY2019	idya	Conversion Of Redeemable Convertible Preferred Stock In To Common Stock ConversionOfRedeemableConvertiblePreferredStockInToCommonStock	138391000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176700000
CY2021Q4	idya	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	368100000
CY2021	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There have been no such impairments of long-lived assets for the years ended December 31, 2021 and December 31, 2020. </p>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</p>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Substantially all the Company’s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment policy addresses credit ratings, diversification, and maturity dates. The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable represents amounts due from GlaxoSmithKline. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection.</p>
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	276017000
CY2021Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	368554000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	367842000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	216541000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	14000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	216548000
CY2020Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	283606000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10360000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	276729000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	720000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	14000
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	283613000
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0
CY2020Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8165000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5597000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3894000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4763000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4271000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1700000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1400000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000
CY2021Q4	idya	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	7864000
CY2020Q4	idya	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	5259000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3971000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2685000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	485000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	543000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12320000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8516000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1982000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2036000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1647000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5665000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	484000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5181000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1699000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3482000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5181000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1700000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1900000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1700000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	1500000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	1500000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3900000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5200000
CY2021Q4	idya	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	825000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1700000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.007
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.019
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.070
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.252
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.314
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.038
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.027
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.036
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.004
CY2021	idya	Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockLiability	0.000
CY2020	idya	Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockLiability	0.000
CY2019	idya	Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockLiability	0.002
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27324000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13418000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5939000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3813000
CY2021Q4	idya	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1097000
CY2020Q4	idya	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1420000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1179000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1274000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1725000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	705000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	882000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	505000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	12575000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	17332000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	50721000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38467000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49575000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36879000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1146000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1588000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	901000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	73000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	330000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1304000
CY2020Q4	idya	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	1100000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	321000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	746000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	153000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock is entitled to one vote.
CY2021Q4	idya	Number Of Common Stock Voting Rights Held Per Share NumberOfCommonStockVotingRightsHeldPerShare	1
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	0
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5146427
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3924191
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.36
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8237000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3609000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2168000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.09
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.16
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	22200000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M9D
CY2021	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0
CY2020	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	10518
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	idya	Gross Increase In Accounts Receivable During Period GrossIncreaseInAccountsReceivableDuringPeriod	986000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	60232000
CY2021	idya	Reimbursement Period Of Costs Incurred ReimbursementPeriodOfCostsIncurred	P75D
CY2021	idya	Number Of Additional Customer Options NumberOfAdditionalCustomerOptions	2
CY2021	idya	Collaboration Revenue CollaborationRevenue	27941000
CY2020	idya	Collaboration Revenue CollaborationRevenue	19538000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	83773000
CY2021	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	27941000
CY2021	idya	Cash Received For Cost Reimbursement CashReceivedForCostReimbursement	3414000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	64157000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49762000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-34495000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-41975000
CY2021	idya	Weighted Average Number Of Shares Issued Basic And Diluted WeightedAverageNumberOfSharesIssuedBasicAndDiluted	35262987
CY2020	idya	Weighted Average Number Of Shares Issued Basic And Diluted WeightedAverageNumberOfSharesIssuedBasicAndDiluted	24783287
CY2019	idya	Weighted Average Number Of Shares Issued Basic And Diluted WeightedAverageNumberOfSharesIssuedBasicAndDiluted	12669367
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	10544
CY2020	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	61512
CY2019	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	172410
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35252443
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24721775
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12496957
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.41
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.40
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3620666
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2620541
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2061921
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2021	idya	Defined Contribution Plan Plan Name Extensible Description DefinedContributionPlanPlanNameExtensibleDescription	401(k) plan
CY2020	idya	Defined Contribution Plan Plan Name Extensible Description DefinedContributionPlanPlanNameExtensibleDescription	401(k) plan
CY2019	idya	Defined Contribution Plan Plan Name Extensible Description DefinedContributionPlanPlanNameExtensibleDescription	401(k) plan
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000

Files In Submission

Name	View Source	Status
0001564590-22-010922-index-headers.html	Edgar Link	pending
0001564590-22-010922-index.html	Edgar Link	pending
0001564590-22-010922.txt	Edgar Link	pending
0001564590-22-010922-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gseklct2vpny000001.jpg	Edgar Link	pending
idya-10k_20211231.htm	Edgar Link	pending
idya-10k_20211231_htm.xml	Edgar Link	completed
idya-20211231.xsd	Edgar Link	pending
idya-20211231_cal.xml	Edgar Link	unprocessable
idya-20211231_def.xml	Edgar Link	unprocessable
idya-20211231_lab.xml	Edgar Link	unprocessable
idya-20211231_pre.xml	Edgar Link	unprocessable
idya-ex1018_64.htm	Edgar Link	pending
idya-ex231_8.htm	Edgar Link	pending
idya-ex311_9.htm	Edgar Link	pending
idya-ex312_7.htm	Edgar Link	pending
idya-ex321_6.htm	Edgar Link	pending
idya-ex43_86.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IDYA
IDEAYA Biosciences, Inc. Stock $idya

2022 Q1 Form 10-K Financial Statement

#000156459022010922 Filed on March 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IDYA IDEAYA Biosciences, Inc. Stock $idya

2022 Q1 Form 10-K Financial Statement

#000156459022010922 Filed on March 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IDYA
IDEAYA Biosciences, Inc. Stock $idya